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Introduction
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection (1). As 
of  2017, sepsis accounted for 11 million deaths worldwide (2). Many efforts have focused on developing 
therapeutic targets, but relatively effective treatments for sepsis are lacking.
In defense against microbial infection, innate immune cells are activated, causing neutrophil extracellular 
trap (NET) formation (NETosis, a programmed neutrophil death) and macrophage pyroptosis (an inflamma-
tory cell death). NETosis sequesters bacteria for pathogen inactivation (3), and pyroptosis is an antimicrobial 
response that mainly takes place in macrophages. Although uncontrolled immune cell death has recently been 
considered as a significant contributing factor to sepsis pathogenesis (4–6), it is presently unknown whether 
manipulation of  the regulation of  NETosis and/or pyroptosis influences sepsis progression.
Peptidylarginine deiminases (PADs) are a family of  calcium-dependent enzymes that promote the 
conversion of  the basic amino acid residue arginine to a neutral residue citrulline. The 5 PAD isozymes 
(PAD1–PAD4 and PAD6) share overlapping substrates. Due to their function in citrullinated proteins, 
PADs are involved in a variety of  physiological processes, including gene expression, immune response, 
and cell signaling (7). Among the PADs, PAD2 and PAD4 are highly expressed in neutrophils (8) and 
macrophages (9), and they are widely involved in immune-related activity. PAD4 is involved in the sig-
naling pathway of  NETosis (10), but Pad4-deficient mice are not protected in models of  sepsis (11). 
Peptidylarginine deiminases (PADs) are a family of calcium-dependent enzymes that are involved in 
a variety of human disorders, including cancer and autoimmune diseases. Although targeting PAD4 
has shown no benefit in sepsis, the role of PAD2 remains unknown. Here, we report that PAD2 is 
engaged in sepsis and sepsis-induced acute lung injury in both human patients and mice. Pad2–/– or 
selective inhibition of PAD2 by a small molecule inhibitor increased survival and improved overall 
outcomes in mouse models of sepsis. Pad2 deficiency decreased neutrophil extracellular trap 
(NET) formation. Importantly, Pad2 deficiency inhibited Caspase-11–dependent pyroptosis in vivo 
and in vitro. Suppression of PAD2 expression reduced inflammation and increased macrophage 
bactericidal activity. In contrast to Pad2–/–, Pad4 deficiency enhanced activation of Caspase-11–
dependent pyroptosis in BM-derived macrophages and displayed no survival improvement in a 
mouse sepsis model. Collectively, our findings highlight the potential of PAD2 as an indicative 
marker and therapeutic target for sepsis.
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Interestingly, pan-PAD inhibitors have been shown to improve survival in a mouse model of  sepsis (12), 
suggesting that PADs other than PAD4 may play a key role in pathogenesis of  sepsis. Furthermore, 
recent studies have shown that PAD2 inhibition is beneficial in several animal models of  diseases, includ-
ing lupus, colitis, cancer, and hemorrhagic shock (13, 14). However, the relationship between PAD2 and 
sepsis is still elusive.
In this study, we assessed the expression of  PAD2 in human septic patients. Using Pad2–/– mice or mice 
treated with a selective PAD2 inhibitor, AFM32a, we evaluated the impact of  PAD2 on survival and out-
comes in animal models of  sepsis. We also determined the effects of  PAD2 on neutrophil NET formation 
and macrophage Caspase-11–dependent pyroptosis (noncanonical pyroptosis).
Results
PAD2 protein is increased in patients with sepsis and in a mouse model of  sepsis. To investigate whether PAD2 
protein is upregulated in sepsis, we measured PAD2 protein in serum samples collected from patients with 
sepsis at study enrollment and at 24 and 48 hours after enrollment. The serum of  healthy volunteers served 
as a negative control. Circulating PAD2 was increased in patients with sepsis compared with healthy con-
trols. This increase was significant and persisted for about 48 hours (Figure 1A).
Further analysis showed that the serum concentration of  PAD2 in patients was positively correlated 
to lactate (r = 0.5, P = 0.04) (Figure 1B) and procalcitonin (PCT) levels (r = 0.67, P = 0.003) (Figure 1C). 
Since acute respiratory distress syndrome (ARDS) is a common complication in sepsis, we measured levels 
of  PAD2 in bronchoalveolar lavage fluid (BALF) that was collected from patients within 7 days of  the diag-
nosis of  sepsis-induced ARDS. Consistent with serum samples, PAD2 protein in BALF from the ARDS 
patients was also significantly increased compared with the healthy control group (Figure 1D).
Next, we determined whether PAD2 protein was elevated in a murine model of  cecal ligation and 
puncture–induced (CLP-induced) lethal sepsis. Consistent with our findings from patients with sepsis, 
PAD2 was also upregulated in serum and lung tissue after CLP (Figure 1, E and F). Our results suggest that 
PAD2 is involved in the pathogenesis of  human sepsis and may participate in the underlying mechanisms 
that lead to sepsis-induced end organ damage.
Pad2 deficiency improves survival in the mouse model of  CLP-induced sepsis. To understand the role of  PAD2 in 
sepsis, we first assessed whether Pad2 gene KO would impact mortality in the murine CLP model. Compared 
with WT mice, the survival rate of  Pad2–/– mice was significantly improved for both sexes (Figure 2A and 
Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/
jci.insight.138873DS1). In addition, WT mice treated with the PAD2 selective inhibitor AFM32a had a sig-
nificant increase in survival compared with vehicle controls (Figure 2B). Our results indicate that inhibition 
of  PAD2 expression can significantly improve survival in the murine model of  CLP-induced sepsis.
Pad2–/– enhances bacterial clearance and improves organ functions in the murine CLP-induced sepsis model. 
To further evaluate outcomes in the murine CLP model, several pathological parameters were assessed. 
Compared with WT mice, the bacterial CFU in the abdominal cavity of  Pad2–/– mice were significantly 
decreased by more than 1000-fold at 24 hours following CLP (Figure 3A). Decreased bacterial dissemi-
nation in Pad2–/– mice was also evident in the blood and spleen with a nearly 10,000- and 100-fold decline 
in CFU compared with WT control animals, respectively. To determine whether the reduced bacterial 
load may partly result from the altered activity of  phagocytes (macrophages and neutrophils), we assessed 
phagocytic function of  Pad2-deficient BM-derived macrophage (BMDMs), peritoneal macrophages, and 
neutrophils. Compared with WT macrophages, Pad2-deficient BMDMs and peritoneal macrophages dis-
played enhanced phagocytosis (Figure 3, B and C; and Supplemental Figure 2, A and B), as shown by the 
significantly increased uptake of  E. coli bioparticles. Neutrophils, however, showed similar phagocytosis 
capacity in WT and Pad2–/– mice (Supplemental Figure 2, C and D).
It is known that enhanced permeability of  the endothelial barrier and subsequent microvascular leakage 
are signs of  the advanced stages of  sepsis (15). Therefore, we examined the microvascular permeability of  
different organs. Pad2–/– significantly reduced CLP-induced permeability in lung and kidney, and it showed a 
trend toward the decreased permeability in spleen and liver (Figure 4A), suggesting that KO of  the Pad2 gene 
could ameliorate sepsis-induced organ dysfunction by reducing microvascular permeability.
Given that the main cause of  death in sepsis is dysfunction of  vital organs — brought about by syndromes 
such as ARDS (16), a severe form of acute lung injury (ALI) — we performed H&E staining of  pulmonary 
tissues and evaluated the pathological changes of  ALI 24 hours after CLP. As shown in Figure 4B, the WT 
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control mice displayed normal histology, while the lungs from WT-CLP group exhibited obvious inflamma-
tory changes (e.g., inflammatory infiltrates, alveolar hemorrhage, pulmonary congestion, edema, and thicken-
ing of  the alveolar wall). However, the sepsis-induced ALI was significantly attenuated in the Pad2–/– group, 
as shown by the significantly reduced ALI score (Figure 4C). IHC experimentation further demonstrated the 
extensive infiltration of  neutrophils and macrophages in lung tissues after CLP. Pad2 deficiency significantly 
reduced neutrophil infiltration, but the numbers of  macrophages were not changed between the WT and 
Pad2–/– groups (Supplemental Figure 3). Moreover, proinflammatory cytokines such as macrophage inflam-
matory protein 2 (MIP-2), IL-6, and IFN-γ–induced protein 10 (IP-10) were dramatically decreased in BALF 
of Pad2–/– mice (Figure 4D). Overall, the results of  survival, bacterial loading, vascular permeability, and ALI 
score strongly indicate that PAD2 is vital for sepsis pathogenesis and that its inhibition could serve as a poten-
tial therapeutic target for sepsis.
Pad2–/– decreases NET formation. We then explored mechanisms behind Pad2–/– reduction in mortality 
and sepsis-induced organ injury in mice. Since PAD4 is a well-known key enzyme for NET formation, 
leading to vascular and lung injury during sepsis, we hypothesized that PAD2 also regulates NETosis. Since 
double-stranded DNA (dsDNA) is an important marker of  NETs, we measured the concentrations of  dsD-
NA in serum and peritoneal lavage fluid from CLP mice. Although the neutrophil numbers were not much 
changed in the WT and Pad2–/– mice after CLP (Supplemental Figure 4), the dsDNA concentrations in the 
samples of  WT mice were significantly higher than those in the Pad2–/– mice (Figure 5, A and B).
To confirm the relationship between decreased NET formation and Pad2–/–, we next performed in 
vitro studies using neutrophils. We stimulated neutrophils with 2 different agonists involved in NETosis 
pathways: phorbol myristate acetate (PMA) and Ca2+ ionophore (A23187). PMA is known to activate the 
NADPH oxidase–dependent (NOX-dependent) pathway (17–19), and A23187 is known to stimulate the 
Figure 1. PAD2 protein is increased in patients with sepsis and a murine model of sepsis. (A) Levels of serum PAD2 protein in healthy controls and 
patients with sepsis. Serum samples from patients with sepsis collected at enrollment, 24 hours, and 48 hours (n = 13–18/group) were assayed. (B) 
Correlation of serum concentrations of PAD2 protein and lactate in patients with sepsis at enrollment (n = 17). (C) Correlation of serum concentra-
tions of PAD2 protein and procalcitonin (PCT) in patients with sepsis at enrollment (n = 17). The line in the graphs represents the linear fit. (D) Levels 
of PAD2 protein in bronchoalveolar lavage fluid from healthy controls and patients with ARDS (n = 5 for healthy controls and n = 14 for patients with 
sepsis-induced ARDS). (E) Levels of serum PAD2 protein in sham and CLP mice at 12 hours and 24 hours (n = 4–6/group). (F) Western blot results show 
the expression of PAD2 protein in mouse lung tissue with or without CLP (n = 3). Nonnormality data are expressed as minimal to maximal value with 
quantile range (A and D). Data in E are expressed as mean ± SEM. Data with 3 or more groups were analyzed by Kruskal-Wallis test with Dunnett’s 
multiple comparisons test (A) or 1-way ANOVA with Bonferroni’s multiple comparisons test (E). Two groups were analyzed using Mann-Whitney U test 
(D). Correlations between concentrations of PAD2 and lactate or PCT were analyzed using Pearson correlation model. *P < 0.05, **P < 0.01, ***P < 
0.001. The green dots in A and D were values below the lower limit of quantification of the ELISA kit but based on standard curve back calculation.
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NOX-independent pathway (20). To measure the change of  NET release in WT and Pad2–/– neutrophils, 
we used an assay with Sytox Green, the commonly used extracellular DNA dye. Compared with the WT 
group, the release of  NETs was decreased in Pad2–/– neutrophils in response to both PMA and A23187, but 
the kinetics of  release were not changed in Pad2–/– neutrophils (Figure 5C). To confirm this result, immuno-
fluorescence staining and myeloperoxidase-DNA (MPO-DNA) assays were further conducted. The NETo-
sis was reduced in Pad2–/– neutrophils in response to both activators after treatment for 3.5 hours (Figure 
5, D, E, and G; and Supplemental Figure 5). It is well known that CitH3 is a marker of  NETosis. Thus, 
we also examined effect of  Pad2 deficiency on CitH3 production. We found that CitH3+ neutrophils were 
also decreased in Pad2–/– neutrophils after stimulation with both agonists (Figure 5F). Overall, our results 
indicate that Pad2–/– inhibits both NOX-dependent and -independent pathways.
Pad2–/– increases macrophage number and decreases activation of  noncanonical pyroptosis after CLP-induced sep-
sis. Since macrophages display important antimicrobial and proinflammatory properties during sepsis (21), 
we next determined whether PAD2 impacts macrophage activity in sepsis. First, we used flow cytometry 
to detect the macrophage number in the abdominal cavity at 24 hours following CLP. We found that the 
numbers of  live macrophages were significantly elevated in Pad2–/– mice (Figure 6A).
Recent findings suggest that Caspase-11–induced macrophage death (noncanonical pyroptosis) is 
critical for CLP-induced sepsis (22). Therefore, we investigated whether an increase in the number of  live 
macrophages in Pad2–/– mice was related to decreased noncanonical pyroptosis. Our study showed that 
Caspase-11 cleavage was decreased in lung tissue from Pad2–/– mice after CLP (Figure 6, D and E). In 
addition, the peritoneal levels of  IL-1α (Figure 6B) and high-mobility group protein 1 (HMGB-1) (Figure 
6, D and F), markers involved in the noncanonical pyroptosis pathway, were reduced in Pad2–/– compared 
with the WT mice (22, 23). In contrast, levels of  TNF-α, a nonspecific proinflammatory cytokine for the 
noncanonical pyroptosis pathway (Figure 6C), was found to be no different in peritoneal lavage from 
Pad2–/– and WT mice, suggesting a unique role of  PAD2 in Caspase-11 activation. To further confirm 
the involvement of  PAD2-mediated Caspase-11 activation in CLP-induced sepsis, we assessed whether 
Caspase-11–/– mice display altered bacterial load and macrophage numbers similar to that observed in 
Pad2–/– mice. Like Pad2–/– mice, the bacterial clearance in the peritoneal cavity, blood, and spleen of  
Caspase-11–/– mice (Supplemental Figure 6A) was significantly increased, along with an increase of  mac-
rophage numbers (Supplemental Figure 6B) compared with WT mice. Together, these results indicate 
that the loss of  Pad2 function results in a reduction of  noncanonical pyroptosis, thus increasing viable 
macrophage numbers that may contribute to the observed decrease in bacterial load and inflammation 
after CLP in Pad2–/– versus WT mice.
Pad2–/– inhibits noncanonical pyroptosis in BMDMs and the LPS-endotoxic model. To further verify that 
Pad2–/– inhibits noncanonical pyroptosis, BMDMs from WT and Pad2–/– mice were primed and then 
transfected with LPS using a DNA transfection reagent, the standard method to active noncanonical 
Figure 2. Absence of the Pad2 gene or inhibition of PAD2 improves survival in a CLP murine model of sepsis. (A) 
Kaplan-Meier survival curves of WT and Pad2–/– mice subjected to CLP (n = 8/group). (B) Kaplan-Meier survival curves 
of WT mice subjected to CLP that were pretreated with the PAD2 selective inhibitor AFM32a, PAD4 selective inhibitor 
GSK484, or DMSO vehicle (n = 8/group). Values are expressed as survival percentage. ***P < 0.001 by log-rank test.
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pyroptosis pathway in vitro (22). We first assessed whether PAD2 expression is changed during non-
canonical pyroptosis. We found that PAD2 protein levels were upregulated after transfection with 
LPS, while only moderately increased in the LPS-primed group (Figure 7A). In line with in vivo 
studies, Pad2–/– decreased Caspase-11–activated noncanonical pyroptosis, which was manifested by 
reduced LDH release, Caspase-11 cleavage, gasdermin D (GSDMD) cleavage, and IL-1α secretion in 
the Pad2–/– group (Figure 7, B–D). There was no difference in TNF-α levels between WT and Pad2–/– 
groups (Figure 7E).
A small dose followed by a higher concentration of  LPS has been used to mimic noncanonical pyro-
ptosis in vivo (24). Similarly, Pad2–/– mice had significantly decreased IL-1α release and lethality in the LPS 
model, but there was no change in TNF-α release (Figure 7, F–H).
Multiple genes in the noncanonical pyroptosis pathway were also analyzed in the BMDMs of  Pad2–/– 
mice transfected with LPS in vitro. We found that none of  these genes was significantly changed compared 
with the WT group (Supplemental Figure 7). These results imply that Pad2–/– inhibits noncanonical pyro-
ptosis but that this inhibition does not occur through gene regulation.
Pad4–/– does not improve survival in the CLP model but enhances noncanonical pyroptosis activation in vitro. As 
previous studies have shown, Pad4 deficiency may not improve outcomes in polymicrobial sepsis (11). We 
validated this finding in Pad4–/– mice (Supplemental Figure 8) and mice treated with PAD4 selective inhib-
itor GSK484 (Figure 2B). There was no significant difference in survival between WT and Pad4–/– mice, or 
between the mice treated with and without GSK484.
Figure 3. Absence of the Pad2 gene improves bacterial clearance in a CLP murine model of sepsis and enhances phagocytosis in BM-derived macro-
phages (BMDMs). WT and Pad2–/– mice were subjected to CLP. (A) Bacterial loads in peritoneal lavage, blood, and spleen (n = 4–5/group) after 24 hours. 
BMDMs were isolated from WT and Pad2–/– mice and incubated with 1 mg/mL pHrodo Red E. coli BioParticles. (B and C) Fluorescence signal of engulfed 
E. coli bioparticles in peritoneal macrophage (B) and its representative images (C). Values are relative fluorescence units (RFU), calculated from 3 wells 
per group. The results in B and C are representative of 3 independent experiments. Data are expressed as mean ± SEM. Data with 2 groups were analyzed 
using an unpaired 2-tailed Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001. White scale bar: 20 μm. Red scale bar: 10 μm.
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PAD4 is also well known for its function in NET formation. Therefore, we sought to evaluate whether 
the different roles of  PAD2 and PAD4 in sepsis could be attributable to differential activation of  noncanon-
ical pyroptosis. Interestingly, we found that Pad4–/– BMDMs underwent the enhanced noncanonical pyro-
ptosis in an in vitro model, as reflected by increased LDH release, Caspase-11 cleavage, GSDMD cleavage, 
and IL-1α release compared with BMDMs from WT mice; TNF-α levels were not different between WT 
and Pad4–/– groups (Supplemental Figure 9). Our findings revealed that inhibition of  PAD4 can enhance 
Caspase-11–dependent pyroptosis. Taken together, our studies suggest that regulation of  Caspase-11 activa-
tion by PAD2/PAD4 contributes to macrophage noncanonical pyroptosis and animal survival during sepsis.
Discussion
Increasing evidence has highlighted the importance of PAD2 in various immune and inflammatory disorders, 
including rheumatoid arthritis and cancers (25–27). However, little is known about the functions of PAD2 in 
sepsis. In this study, we demonstrated that PAD2 is elevated in serum and BALF of patients with sepsis, as well 
as in the blood and lung tissues of mice subjected to CLP. We found that Pad2 deficiency decreases NETosis 
and macrophage Caspase-11–dependent pyroptosis, thereby increasing macrophage numbers, reducing bacterial 
loads and inflammation, and ultimately increasing survival and organ functions following the onset of sepsis.
Figure 4. Absence of the Pad2 gene attenuates vascular permeability and ALI in a CLP murine model of sepsis. WT and Pad2–/– mice were sub-
jected to CLP. (A) Vascular permeability in lung, kidney, spleen, and liver after 24 hours (n = 4/group) as measured by the weight of EB dye in tissue. 
(B) Representative histology images of murine lungs following H&E staining and (n = 4–5/group). (C and D) ALI score (C) and concentrations of 
MIP-2, IL-6, and IP-10 (D) in the bronchoalveolar lavage fluid (n = 3-6/group). Data are expressed as mean ± SEM. Data with 2 groups were analyzed 
using an unpaired 2-tailed Student’s t test (A), and 3 or more groups were analyzed by 2-way ANOVA with Bonferroni’s multiple comparisons test (C 
and D). *P < 0.05, **P < 0.01, ***P < 0.001. Scale bar: 50 μm.
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Elevated PAD2 correlates with severity of  sepsis and organ injury in human patients and mice. Circulating PAD2 
has been reported in inflammatory states of  coronary artery bypass surgery (28) and arthritis (29). We 
demonstrate in the current study that PAD2 is also elevated in the serum of  septic patients and BALF from 
patients with sepsis-induced ARDS. It is consistent with the findings from our group that the Pad2 gene was 
upregulated in alveolar macrophages and buffy coat cells from patients with ARDS (30). In our study, the 
increased concentration of  PAD2 is associated with high levels of  lactate or PCT, suggesting that PAD2 
Figure 5. Absence of the Pad2 gene inhibits NET formation both in vivo and in vitro. WT and Pad2–/– mice were subjected to CLP. (A and B) The concen-
trations of dsDNA in mouse serum (n = 3 for WT mice without CLP group, n = 5 for WT mice with CLP group, n = 3 for Pad2–/– mice without CLP group, n = 
7 for Pad2–/– mice with CLP group) (A) and peritoneal lavage (n = 4 for WT mice without CLP group, n = 9 for WT mice with CLP group, n = 3 for Pad2–/– mice 
without CLP group, and n = 8 for Pad2–/– mice with CLP group) (B) after 24 hours. BM neutrophils were isolated from WT and Pad2–/– mice and were treated 
with A23187 or PMA. (C) NET formation in response to calcium ionophore and PMA in WT and Pad2–/– neutrophils at different time points (n = 3–5/group). 
(D) Representative immunofluorescence images of the NET formation in WT and Pad2–/– neutrophils after vehicle, Ca2+ ionophore (A23187), or PMA treat-
ment for 3.5 hours. (E and F) Quantification results of immunofluorescence images (n = 6/group). (G) Levels of myeloperoxidase-DNA (MPO-DNA) in cell 
supernatant of WT and Pad2–/– neutrophils after vehicle, A23187or PMA treatment for 3.5 hours. Results are representative of 2 independent experiments 
(C–G). Data are expressed as mean ± SEM. Data were analyzed by 2-way ANOVA with Bonferroni’s multiple comparisons test (A–C and E–G). *P < 0.05, **P 
< 0.01, ***P < 0.001, ****P < 0.0001. Scale bar: 50 μm. Ve, vehicle.
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is correlated with severity of  sepsis and organ injury in human patients (31). In animals, PAD2 protein is 
increased in the LPS-treated BMDM ex vivo and is elevated in serum and lung tissues in the sepsis mouse 
model. It is still not completely clear how and why PAD2 levels are upregulated during sepsis. Recent 
studies revealed that inflammation and bacterial infection induce expression of  PAD2 in macrophages 
and other immune cells (32–34). Upon induction, PAD2 can be actively released or passively leaked (8, 
28) into body fluids, which may cause altered host response to sepsis. Moreover, extracellular PAD2 could 
citrullinate local or circulating proteins (e.g., HMGB1) for further signal transduction (35, 36). Our findings 
highlight a potential role of  PAD2 in NETosis and macrophage pyroptosis in the pathogenesis of  sepsis.
Bacterial clearance regulated by Pad2–/– is not related to NET inhibition. NETosis was first reported by Brink-
mann et al. in 2004 (3). They found that neutrophils release a NET-like structure that can trap and kill bacteria 
during infections. Since then, many researchers reported this “trap” and “bactericidal” effect of  NETosis (37). 
However, the role of  NETosis in bacterial killing during infection has been questioned in recent years. Instead, 
more evidence has emerged to demonstrate that NETs cause more harm than good during infectious process-
es. Menegazzi et al. reported that bacteria released from NETs by DNase remain viable after long-time NET 
exposure (38). Similar results have demonstrated that bacteria bound to PMA-induced NETs also remain 
viable (39). Furthermore, an in vivo study indicates a dispensable bactericidal effect of  NETs (40). PAD4 is 
a pivotal enzyme for NETosis, and its deficiency does not alter mortality nor bacterial load in CLP-induced 
sepsis (11). In our present study, Pad2 genetic deficiency dramatically decreases bacterial load in blood while 
inhibiting NETosis, suggesting that NET formation does not necessarily correlate with bacterial killing.
Pad2 deficiency may attenuate NET-induced inflammation. Inhibiting NETosis or NET components 
during infection appears to be beneficial to the host (41–44). During NETosis, components from dam-
age-associated molecular patterns (DAMPs) such as dsDNA, neutrophil elastase (NE), and histones 
released from neutrophils induce production of  proinflammatory cytokines, increase vascular permeabil-
ity, and cause organ damage (e.g., ALI) (45).
Figure 6. Absence of the Pad2 gene inhibits Caspase-11–dependent noncanonical pyroptosis in a CLP murine 
model of sepsis. WT and Pad2–/– mice were subjected to CLP. (A) Macrophage number in peritoneal cavity of WT 
and Pad2–/– mice after 24 hours (n = 5/group). (B and C) Concentrations of IL-1α (B) and TNF-α (C) in peritoneal 
lavage of WT and Pad2–/– mice after 24 hours (n = 3–7/group). (D–F) Representative Western blot images and 
densitometry quantification of Caspase-11 activation in lung tissues (D and E) and HMGB1 concentration in perito-
neal lavage of WT and Pad2–/– mice (D and F) after 24 hours. Western blot images are representative of at least 3 
independent experiments. Data are expressed as mean ± SEM. Data with 2 groups were analyzed using unpaired 
2-tailed Student’s t test (A). Data with 3 or more groups were analyzed by 2-way ANOVA with Bonferroni’s multiple 
comparisons test (B, C, E, and F). *P < 0.05, ***P < 0.001, ****P < 0.0001.
9insight.jci.org   https://doi.org/10.1172/jci.insight.138873
R E S E A R C H  A R T I C L E
Several previous studies reported that PAD2 is not required for NET formation (46, 47). However, while 
they used low concentrations of  PMA, ionomycin, or LPS to induce small percentage of  NET formation, 
we used higher concentrations of  PMA and A23187 to induce an abundance of  NET formation on the WT 
group. Combined with several ex vivo quantitative research tools (48–50), we found that Pad2 deficiency can 
reduce the speed and quantity of  NET formation, although it does not fully abolish NETosis. Nevertheless, 
by decreasing NET formation, Pad2–/– can decrease the downstream proinflammatory effect, thus mitigating 
vascular permeability and organ damage.
Pad2–/–-induced bacterial clearance may be associated with enhanced phagocytosis and decreased noncanonical 
pyroptosis in macrophages. Macrophages are of  particular interest to our study, since we found that Pad2–/– 
enhances phagocytosis of  macrophages, instead of  neutrophils. In addition, the increased macrophage 
numbers in the peritoneal lavage of  Pad2–/– mice after CLP further indicates a significant change in the 
state of  macrophages. Pyroptosis is an inflammatory form of  cell death that occurs mainly in macrophages. 
Figure 7. Absence of the Pad2 gene inhibits Caspase-11–dependent noncanonical pyroptosis in BM-derived macrophages (BMDMs) and LPS-endotoxic 
model. (A) Representative Western blot images and densitometry quantification show expression of PAD2 in WT mouse BMDMs after noncanonical 
pyroptosis treatment. (B) LDH release in the supernatant of BMDMs after noncanonical pyroptosis treatment. (C) Representative Western blot images 
show Caspase-11 and GSDMD activation in the supernatant and cell lysate of BMDMs with or without noncanonical pyroptosis treatment. (D and E) Con-
centrations of IL-1α (D) and TNF-α (E) in the supernatant of BMDMs with or without noncanonical pyroptosis treatment (n = 3/group). (F) Kaplan-Meier 
survival curve of WT and Pad2–/– mouse in LPS-endotoxic mouse model (n = 14–17/group). (G and H) Concentrations of IL-1α (G) and TNF-α (H) in the 
serum of WT and Pad2–/– mice with or without LPS challenge (n = 3, 8, 3, and 7 for each group, respectively). Results in A–E were representative of at 
least 3 independent experiments. Data are expressed as mean ± SEM. Data with 2 groups were analyzed using unpaired 2-tailed Student’s t test (B). 
Three or more groups were analyzed by 1-way (A) or 2-way (D, E, G, and H) ANOVA with Bonferroni’s multiple comparisons test. Survival curve were ana-
lyzed by log-rank test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. SN, supernatant.
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This form of  cell death can be induced through 2 different signaling pathways: Caspase-1–dependent pyro-
ptosis and Caspase-11–dependent noncanonical pyroptosis. While Caspase-1–mediated pyroptosis plays 
an important role in chronic autoimmune and other inflammatory diseases, Caspase-11–dependent non-
canonical pyroptosis exacerbates pathologies in mouse models of  sepsis (22, 24, 51–53). In this pathway, 
cytosolic LPS from Gram-negative bacterium activates Caspase-11 (Caspase-4/5 in humans) to cleave 
GSDMD, which then triggers cell membrane pore formation and cell death of  macrophages (54, 55). 
Meanwhile, Caspase-11 mediated extracellular release of  IL-1α and HMGB1 directly and induces secre-
tion of  mature IL-1β and IL-18 indirectly through engagement of  the canonical Nlrp3 inflammasome (22, 
23). IL-1α is a typical marker specific in Caspase-11–dependent pyroptosis (22). HMGB1 serves as both a 
marker and mediator in the Caspase-11–dependent pyroptosis pathway (23, 24). It was reported that PAD2 
regulates the activation of  Caspase-1 inflammasome (56), but the effects of  PAD2 on Caspase-11–depen-
dent pyroptosis has not been studied. In our current study, we found that PAD2 activates Caspase-11–
dependent pyroptosis. Pad2 deficiency can significantly decrease Caspase-11 activation both in vitro and in 
vivo. Inhibition of  Caspase-11 activation leads to less IL-1α and HMGB1 release in the peritoneal cavity 
(Figure 6), and it reduces abdominal inflammation during sepsis. Moreover, reduced Caspase-11 activation 
in the absence of  Pad2 protects macrophages from pyroptosis-induced cell death during infection. Such a 
protective effect was also observed in separate experiments using Caspase-11–/– mice as a positive control.
PAD2 is also an important gene regulator that can translocate into the nucleus to convert histone 
H3 to CitH3 and alter gene expression (57, 58). However, our study showed that PAD2 regulated non-
canonical pyroptosis in a manner that is not necessarily through gene regulation. Therefore, protein 
citrullination could be a potential mechanism to explain this effect. For example, HMGB1 has been 
shown to be one of  the most important substrates of  PAD2 (36). Given the important role of  posttrans-
lational modified HMGB1 (e.g., acetylation) in both sepsis and the Caspase-11–dependent pyroptosis 
pathway (24), it is possible that citrullinated HMGB1 by PAD2 could increase its release and further 
activate Caspase-11.
Pad4 deficiency does not alter survival but enhances Caspase-11–dependent pyroptosis. PAD2 and PAD4 are 
very important immune regulators. These proteins may exert synergistic effects on some pathways (such 
as NLRP3 inflammasome activation) (56) while having distinct effects on other pathways (59). Based on 
our result (Supplemental Figure 8) and findings of  others (11), Pad4-KO mice were not protected in experi-
mental mouse sepsis. However, targeting specific components of  NETs can improve survival of  sepsis (41, 
43, 44, 60). Therefore, PAD4 may also be involved in pathways during sepsis other than NETosis. Pad2–/– 
decreases macrophage pyroptosis; therefore, we suspected Pad4 deficiency might also alter the process of  
pyroptosis. Interestingly, we found that Pad4–/– can increase Caspase-11 activation, GSDMD cleavage, and 
IL-1α and LDH release in the BMDM, a typical phenomenon of  noncanonical pyroptosis (Supplemental 
Figure 9). Our study indicates that PAD2 and PAD4 play opposite roles in Caspase-11–dependent pyropto-
sis, which potentially explains the different functions of  PAD2 and PAD4 in sepsis.
In conclusion, to our knowledge, this is the first mechanism study of  Pad2 gene on sepsis. We found 
that PAD2 is elevated in both human septic patients and in mouse sepsis, and Pad2–/– mice or treatment 
of  mice with a PAD2 specific inhibitor can increase the survival and improve outcomes in sepsis. Further-
more, we demonstrated that Pad2–/– inhibits NET formation and Caspase-11–dependent pyroptosis. Given 
the lack of  effective therapeutic targets for sepsis, our study provides insights into the molecular mechanism 
of  PAD2 in pathogenesis and treatment of  sepsis.
Methods
Human subjects. Serum samples of  septic patients were collected from the emergency department or inten-
sive care unit of  University of  Michigan. Patients with the diagnosis of  sepsis were consistent with consen-
sus definitions for severe sepsis or septic shock at the time during collection (61). The sample preparation 
and patient information have been described previously (62).
BALF of  sepsis-induced ARDS patients was collected from the ALI Specialized Center of  Clinically 
Oriented Research (SCCOR) as a part of  randomized trial of  granulocyte-macrophage CSF administration 
(ClinicalTrials.gov NCT00201409) conducted at the University of  Michigan (63). The sample preparation 
and patient information have been described previously (64).
Healthy volunteers were asymptomatic, ambulatory nonsmokers under 60 years of  age, who had no 
known chronic medical conditions and were taking no medications.
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Mice. All experiments were performed using 8- to 12-week-old male mice unless otherwise men-
tioned. Pad2-KO mice generated on FVB/NJ background were provided by Scott Coonrod (Cornell 
University, Ithaca, New York, USA). Caspase-11–/– mice generated on a C57BL/6J background were 
provided by Gabriel Nunez (University of  Michigan). FVB/NJ and C57BL/6J WT mice were pur-
chased from the Jackson Laboratory and used as controls for Pad2–/– mice and Caspase-11–/– mice in 
all studies. Pad4–/– mice were generated on C57BL/6J × SJL mixed background in our laboratory and 
were backcrossed into C57BL/6J for 7 generations before experiments. Littermate WT mice were used 
as controls in the experiment. All animal experiments were performed with an approval from the Uni-
versity of  Michigan (PRO00008861).
Development of  PAD4-KO mice. PAD4-KO mice were generated using CRISPR/Cas9 technology. Brief-
ly, A premature stop codon followed by a unique restriction motif  (for genotyping) was inserted near the 
start codon of  PAD4 gene, which would result in a halted translation following residue 10. The deleted 65 
bp genomic sequence is as follows: 5′-CGGACATCCAGCGGGGTCGCTGTGCCCACCACACACAC-
GGCGTGAGTGGGCTGCTCGGGGGCCAC-3′. Then, a 14 bp sequence was inserted at the same site, 
which is 5′-AATTCTCATTATCA-3′. Afterward, these generated PAD4-KO mice were mated with WT 
mice of  C57BL/6J background to establish germline transmission. Resultant heterozygotes were used to 
generate homozygotes of  PAD4-KO mice.
ELISA. Levels of  PAD2 were measured using a commercial ELISA kit (PAD2 [human], Cayman 
Chemical, 501450; PAD2 [mouse], Aviva Systems Biology, OKCA02444). PCT concentrations were 
detected with a commercial ELISA kit (R&D Systems Inc., DY8350-05). All measurements were carried 
out in accordance with the industrial instruction. Concentrations of IL-1α, TNF-α, MIP-2, IL-6, and IP-10 
were measured by the ELISA core of  University of  Michigan using the core-developed sandwich ELISA.
CLP polymicrobial sepsis model. Sepsis was induced by CLP. Briefly, the peritoneal cavity was opened 
under inhaled isoflurane anesthesia. The cecum was eviscerated, ligated below the ileocecal valve using a 
5-0 silk suture at 75% from the tip, and punctured through with a 21-gauge needle. Sham-operated animals 
were handled in the similar manner, except the cecum was not ligated and punctured. For the survival 
study, mice were monitored for 7 days. For mechanistic studies, mice were sacrificed at their respective 
time point. For inhibitor analysis, PAD4 inhibitor GSK484 (40 mg/kg) (Cayman Chemical, 17488), PAD2 
inhibitor AFM32a (20 mg/kg), which was synthesized as previously described (65), or DMSO alone was 
i.p. injected 1 hour after CLP.
Bacterial burden determination. Mice were euthanized 24 hours after CLP, and the peritoneal cavity was 
washed with 2 mL sterile PBS. Blood was collected through cardiac puncture, and the spleen was harvested 
and then homogenized in 1 mL sterile PBS (Gibco, Thermo Fisher Scientific). The blood, peritoneal lavage 
fluid, and spleen homogenate were then serially diluted in sterile PBS. The resulting diluent (100 μL) was 
plated onto tryptic soy agar plates and incubated at 37°C for 16 hours. Plates with colony numbers among 
30–300 were counted. Results were expressed as CFU per milliliter blood, peritoneal lavage fluid, and 
spleen homogenate.
Isolation of  peritoneal macrophage. Peritoneal macrophages were harvested in the mouse model of  thiogly-
collate-induced sterile peritonitis (66). Briefly, 1.5 mL of  4% Brewer thioglycollate was peritoneally injected 
into mice. The animals were euthanized 3 days later, and the peritoneal cavity was flushed with 10 mL of  
cold PBS. Peritoneal macrophages were further collected after centrifugation (4°C, 400g, 10 minutes).
Phagocytosis assay. The phagocytotic ability of  macrophages and neutrophils was evaluated using pHro-
do Red E. coli BioParticles (Thermo Fisher Scientific, P35361). In brief, 2 × 105 or 3 × 105 cells per well 
were plated in a blank 96-well plate, and pHrodo Red E. coli BioParticles were suspended in living imaging 
solution at 1 mg/mL and sonicated to make it homogeneously dispersed. The macrophages and neutro-
phils were then coincubated with a bioparticle suspension for 1–1.5 hours at 37°C. Quantitative results 
were read using fluorescence plate reader (Promega, E8032). Mean values are RFU, calculated from 3–4 
wells per group, and subtracting the baseline fluorescence from wells containing pHrodo E. coli BioParticles 
but no cells (means ± SEM). Representative images were obtained using a fluorescence microscope (Olym-
pus, DP70). Six microscopic fields were randomly chosen from each group.
Vascular permeability assay. Microvascular permeability was evaluated by the Evans Blue (EB) assay. In 
brief, 1% EB in normal saline (4 mL/kg) was injected to mice through tail veins 18 hours after CLP. Mice 
were sacrificed after 30 minutes and perfused with 25 mL PBS. Tissues were harvested, and 50–100 mg tis-
sue of  each organ was homogenized with 500 μL dimethylformamide (DMF) and then incubated at 55°C 
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for 27 hours. Tissue lysates were centrifuged at 4°C and 7000g for 10 minutes, and the supernatant was col-
lected for optical density (OD) measurement at A620. The accurate EB weight for each organ was further 
quantified according to a standard curve made by serial dilution of  known concentration of  EB solution.
Lung injury analysis and IHC. Mice were euthanized 24 hours after CLP. For inflammatory cytokine 
detection, the lungs were flushed with 3 mL sterile HBSS to get the BALF samples. Inflammatory cytokines 
in the BALF were detected using ELISA. For histological analysis of  ALI, the lung tissues were embedded 
in paraffin and sliced into 5 μm sections. H&E staining was performed for histology detection. The ALI 
scoring was conducted by a pathologist blinded to the experiment groups. ALI was classified into 6 cate-
gories based on the parameters of  (a) neutrophils, (b) septal hemorrhage and congestion, (c) septal mono-
nuclear cell/lymphocyte infiltration, (d) alveolar hemorrhage, (e) alveolar macrophages, and (f) alveolar 
edema. The severity of  each category was graded from 0 (minimal) to 3 (maximal), and the total score was 
calculated by adding the scores in each of  these categories.
Immunohistochemical staining of  macrophages (F4/80+) and neutrophils (MPO+) were performed 
using Immunohistochemistry Application Solutions Kit (Rabbit) (Cell Signaling Technology, 13079) accord-
ing to the manufacturer’s instruction. Anti-F4/80 (Cell Signaling Technology, 70076S, 1:1000) and anti-
MPO (Abcam, ab9535, 1:400) were used as primary antibodies. Negative controls for immunohistochemical 
analysis were the sections incubated with antibody dilution buffer without the primary antibodies, which 
showed no positive staining. The positively stained cells were counted from 3 different areas under high-pow-
er field (×400), and the final positive cell numbers of  each slides resulted from the average of  the 3 areas.
Serum levels of  dsDNA measurement. The PicoGreen assay kit (Invitrogen, Thermo Fisher Scientific, 
P11495) was used to detect circulating dsDNA per manufacturer’s instructions. Briefly, the serum was incu-
bated with the PicoGreen assay reagent for 5 minutes and then quantified with fluorescence plate reader.
NETosis induction and detection. Neutrophils used in this study were BM neutrophil isolated using Easy-
Sep Mouse Neutrophil Enrichment Kit (Stemcell Technologies, 19762). Cells were suspended with HBSS 
with calcium chloride/magnesium chloride and 2% FBS. NETosis was induced using Calcium Ionophore 
(A23187, 25 μM) or PMA (100 nM).
For the plate-reader assay, cells were seeded at 1 × 105 cells per well in a blank 96-well plate in the 
presence of  5 μM Sytox Green. The fluorescence was measured by a fluorescence plate reader (Promega, 
E8032) at 1-hour time intervals for up to 8 hours after cell activation. For the NETosis index, a fluorescence 
readout obtained from cells lysed using 0.33% Triton-100 was considered as 100% DNA release, and a sig-
nal from the untreated group was considered as from spontaneous DNA release. The index was calculated 
as the percentage of  total DNA released after subtracting the background signal (49).
For visualization of  NETs, 8-well chamber slides were coated with poly-l-lysine and seeded with 1 × 105 
cells per well. After treatment with PMA or Calcium Ionophore for 3.5 hours, the cells were fixed and per-
meabilized with neutral-buffered formalin and methanol. Cells were blocked with 3% BSA prepared in PBS 
for 1 hour at room temperature and then incubated with primary antibodies overnight at 4°C and respective 
secondary antibodies for 1 hour at room temperature. DNA was stained with mounting medium contain-
ing DAPI. The primary antibodies used were CitH3 (4D5D6) (60) and MPO (Abcam, 9535). Imaging was 
obtained using a fluorescence microscope (Olympus, BX53). Six microscopic fields were randomly chosen 
from each group, and the percentage of  CitH3+ neutrophils or those undergoing NETosis was determined by 
blinded manual counting.
MPO-DNA assay. To quantify the MPO-DNA complex in the cell supernatant, a capture ELISA based on 
MPO associated with DNA was performed (50). Cell supernatant was pretreated with limited DNase digestion. 
Anti-MPO antibody (Invitrogen, Thermo Fisher Scientific, PA5-16672, 1:1000) was coated overnight as a cap-
ture antibody. After blocking, the diluted cell supernatant was then added to the plate and incubated at room 
temperature for 3 hours. Peroxidase-labeled anti-DNA monoclonal antibody (Roche, Cell Death Detection ELI-
SA, 11544675001) was used as the detection antibody. After incubating for 1.5 hours at room temperature, the 
peroxidase substrate (TMB) was added, and the reactions were then ended by stop solution. The final results 
were shown as the OD value at 450 nm measured by microplate reader (Molecular Devices, Spectra Max Plus).
Flow cytometry. Peritoneal immune cell numbers were measured using flow cytometry. Peritoneal 
cavities were flushed with cold PBS and then filtered through a 70 μm cell strainer to get rid of  leak-
ing feces. Next, total peritoneal cells were counted and stained with specific fluorochrome-conjugat-
ed monoclonal antibodies (all from BioLegend) (F4/80, 123115; CD45, 103137; Ly6G, 45-5931-80; 
CD11b, 101223). Dead cells were excluded according to 7-ADD staining (BD Pharmingen, 51-68981E). 
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Fluorescence data were acquired on a LSRFortessa Flow Cytometer (BD Biosciences) and analyzed 
using FlowJo software (Tree Star Inc.).
Blood neutrophil count. Mouse blood neutrophils were counted using VETSCAN HM5 Hematology 
Analyzer according to the manufacturer’s instruction.
Isolation of  BMDMs. BMDMs were generated using well-established protocols. In brief, BM cells were 
flushed out of  mouse legs with 60 mL of  complete medium of  IMDM supplemented with 20% L929 cell 
medium, penicillin, streptomycin, 2-mercaptoethanol, glutamine, and 10% heat-inactivated fetal calf  serum 
(Gibco, Thermo Fisher Scientific). The fresh completed medium (30 mL) was added at day 3. Adherent 
BMDMs were harvested at day 7 and then used for following experiments.
Macrophage transfection. BMDMs were plated in a 6-well plate at 1 × 106 cells per well. Cells were first 
primed with 50 ng/mL LPS in Opti-MEM overnight. For LPS transfection, 1.5 μg of LPS were packed with 
7.5 μL of DOTAP after 30 minutes of incubation at room temperature, and the mixture was diluted into 1 mL 
of Opti-MEM before adding to 6-well plates. IL-1α and TNF-α release in cell-free supernatant was measured by 
ELISA. Cell lysate was analyzed by Western blot with antibodies against Caspase-11, GSDMD, and β-actin.
Lactate dehydrogenase (LDH) assay. LDH released from pyroptotic cells was measured by a Cytotoxicity 
Detection LDH Kit (Roche, 11644793001). In brief, 10,000 BMDMs per well were seeded in a 96-well plate 
and treated with or without LPS transfection. For LDH release detection, 100 μL supernatant was collected 
from each well. After centrifugation (4°C, 350g, 5 minutes), 100 μL of the kit’s reaction mixture were added and 
coincubated for 30 minutes in the dark. The microplate reader (Molecular Devices, Spectra Max Plus) was used 
to measure the OD at 490 nm. The final LDH release was calculated according to the manufacturer’s protocol.
Endotoxemia mouse model. The endotoxemia mouse model was induced through 2 shot LPS; mice were 
first injected i.p. with a low dose of  LPS (400 μg/kg) (MilliporeSigma, L2630) for 6 hours and then chal-
lenged with a high dose of  LPS (4 mg/kg). For survival study, mice were monitored for 7 days. For serum 
cytokine detection, mice were sacrificed 4 hours after the second LPS challenge.
Western blotting. The antibodies were purchased from the following: anti-PAD2 (Proteintech, 12110-
1-AP), anti–Caspase-11 (Abcam, 180673), anti–GSDMD (Abcam, 209845), and anti-HMGB1 (Abcam, 
ab18256). Cell and tissue lysates were prepared using radioimmunoprecipitation assay (RIPA buffer). Pro-
tein in cell supernatant were precipitated by deoxycholate-trichloroacetic acid method, and Ponceau S 
staining was used as loading control. For peritoneal lavage preparation, 30 μL peritoneal lavage with 6 μL 
6× loading buffer were directly used as loading samples. Since there is no ideal loading control for perito-
neal lavage, a loading volume of  30 μL sample was fixed in all groups.
Quantitative PCR. Total RNAs were extracted using RNeasy Mini Kit (QIAGEN, 74104) and were 
reverse-transcribed into cDNA (Applied Biosystems, Thermo Fisher Scientific, 4368814). Quantitative 
PCR was performed with iQ SYBR Green Supermix (Bio-Rad). Gene expression was normalized against 
the internal control GAPDH. The primer sequences are shown in Supplemental Table 1.
Statistics. Statistical analyses were performed using Prism software (GraphPad). Normality of  
human data pools was tested with the Pearson-D’Agostino normality test. As for nonnormality distri-
bution, Kruskal-Wallis test with Dunnett’s multiple comparisons test were used to compare multiple 
groups. Mann-Whitney U test was used to compare 2 groups. Association of  PAD2 with lactate and 
PCT were studied using a Pearson regression model. For other in vivo and in vitro studies, when the 
sample number was too small for normality detection, the 1-way or 2-way ANOVA with Bonferroni’s 
multiple comparisons test was used to compare multiple groups. An unpaired 2-sided t test was used to 
compare 2 groups. Survival curves were analyzed by log-rank test. A P value less than 0.05 was consid-
ered significant for all experiments.
Study approval. All animal studies were reviewed and approved by the University Committee on the 
Use and Care of  Animals (University of  Michigan; PRO00008861 and PRO00008239). Human studies 
used protocols approved by the University of  Michigan IRB (HUM 00056630, IRB 2003-0430, and IRB 
2003-0829). Written informed consent was obtained from all participants or their legal proxy for medical 
decision-making before study inclusion.
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